COVID-19 vaccines and kidney diseaseShow others and affiliations
2021 (English)In: Nature Reviews Nephrology, ISSN 1759-5061, E-ISSN 1759-507X, Vol. 17, no 5, p. 291-293Article in journal, Editorial material (Refereed) Published
Abstract [en]
Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.
Place, publisher, year, edition, pages
NATURE RESEARCH , 2021. Vol. 17, no 5, p. 291-293
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-173694DOI: 10.1038/s41581-021-00406-6ISI: 000616034300001PubMedID: 33558753OAI: oai:DiVA.org:liu-173694DiVA, id: diva2:1532803
Note
Funding Agencies|Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [AN372/24-1]; Intramural Research Program of the NIH, NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
2021-03-022021-03-022022-05-26